



MedImmune (Gaithersburg, MD, USA) has announced the appointment of **Peter S. Greenleaf** (left) as senior vice president, marketing and sales, with responsibility for leading the company's global commercial organization. Mr. Greenleaf was most recently a vice president for Centocor, heading the company's gastroenterology commercial operation.

In addition, MedImmune has named **Sidney Mazel** to the newly created position of senior vice president, product planning and portfolio management. Dr. Mazel previously held a number of senior leadership positions at Merck & Co., most recently serving as vice president of worldwide marketing planning for Merck's obesity and atherosclerosis franchise.



**Steven Mermelstein** (left) has joined the investment banking firm Ferghana Partners. As managing director, he will work on M&A and corporate partnering transactions, as well as the develop-

ment and execution of private equity financings. Mr. Mermelstein most recently served as managing director at Asanté Partners. From 1999 to 2003, he was a director at Wasserstein Perella & Co., and before that, spent over ten years at Chase Manhattan Bank.

**Gabor M. Rubanyi** has been named CSO at Cardium Therapeutics (San Diego). Before joining Cardium, Dr. Rubanyi was vice president of gene therapy at Berlex Biosciences and adjunct professor at the University of California, Davis.

Quantum Genomics (Jersey City, NJ, USA) has announced that it has appointed **Lionel Ségard** as CEO. Dr. Ségard was previously CEO of Inserm-Transfert, the technology transfer arm of France's national health research center.

Nanobiotech company pSivida (Boston, and Perth, Australia) has announced the appointments of **Michael J. Soja** as vice president, finance and CFO, and **Lori H. Freedman** as vice president, corporate affairs, general counsel and secretary. Both Mr. Soja and Ms. Freedman are based at pSivida's Boston facility. Mr. Soja was previously vice president, finance and CFO of Control Delivery Systems, which was acquired by pSivida in December 2005. Ms. Freedman is the former vice president, corporate affairs, general counsel and secretary of Control Delivery Systems.

Oncolytics Biotech (Calgary, Alberta, Canada) has announced the appointment of **Ger J. van Amersfoort** to the company's board of directors. Until his retirement in 2001, Mr. van Amersfoort served as president and CEO of Novartis Canada. Before joining Novartis, he was president and CEO of SmithKline Beecham's UK operations from 1997 to 1999.

Affibody (Stockholm) has named **Ulf Boberg** CEO, replacing **Carl-Johan Dalsgaard** who has been acting CEO since December 2005. Dr. Dalsgaard, a partner with Affibody's largest shareholder HealthCap, will remain as a nonexecutive board member. Dr. Boberg joined Affibody in January 2006 as senior vice president, development, after serving as CEO of Global Genomics.

Illumina (San Diego, CA, USA) has named **Christian G. Cabou** senior vice president and general counsel. He was most recently general counsel of GE Global Research, the research arm of General Electric Company, and previously senior counsel of global intellectual property of GE Medical Systems. Before GE, Mr. Cabou spent nearly seven years with the firm of Foley & Lardner.

**Jacques Essinger** has been appointed president of the supervisory board of Trophos (Marseille, France). Dr. Essinger has over 20 years of experience in the biomedical industry. As CEO of Modex Therapeutics, he guided the company through its initial public offering and two M&A transactions, after which it became Isotis Orthobiology.

**Eric T. Fung** has been promoted to the position of CSO at CIPHERGEN Biosystems (Fremont, CA, USA). In addition, Dr. Fung will chair the newly formed scientific advisory board. Dr. Fung joined the company in 2000 as a lead scientist, and served most recently as vice president of clinical and medical affairs.

MicroIslet (San Diego) has announced the

permanent appointment of **James R. Gavin III** as president and CEO of the company. Dr. Gavin was named interim president and CEO in January 2006, and has been a member of MicroIslet's board of directors since March 2001. He serves as a director for several organizations, including Baxter International, Amylin Pharmaceuticals and Nuvelo Pharmaceuticals.

**Peter A. Harris** has joined OXiGENE (Waltham, MA, USA) in the newly created role of chief medical officer. Dr. Harris has more than 25 years of experience, most recently serving as a development director for KuDOS Pharmaceuticals, now a wholly owned subsidiary of AstraZeneca. He previously served as director of clinical research in Europe for Amgen.

Motif BioSciences (New York) has named **Zaki Hosny** deputy chairman and CEO. Mr. Hosny has more than three decades of experience in the pharmaceutical industry, most recently at Merck & Co. where he held the position of vice president of marketing and operations for Europe, the Middle East and Africa. Mr. Hosny succeeds **Stephen Cass** as CEO of Motif.

**John Maraganore** has been appointed to the board of directors of Archemix (Cambridge, MA, USA). Currently the president and CEO of Alnylam Pharmaceuticals, he previously served as senior vice president, strategic product development for Millennium Pharmaceuticals. Dr. Maraganore also serves on the board of directors of the Biotechnology Industry Organization.